The global Clinical Trial Protocol Design AI market is experiencing rapid momentum as pharmaceutical companies, CROs, and biotech innovators increasingly adopt artificial intelligence to optimize clinical trial planning. According to Market Intelo’s latest study, the market was valued at USD 412.6 million in 2024 and is projected to reach USD 2.87 billion by 2032, growing at a CAGR of 27.6% during the forecast period. As AI-driven analytics, predictive modeling, and digital simulation tools evolve, the sector is primed to play a transformative role in reshaping global clinical research.